Jump to top menu Jump to main menu Jump to content
News

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

November 25, 2021

9 November

Sjoukje F Oosting, MD, Astrid A M van der Veldt, MD, Corine H GeurtsvanKessel, MD, Rudolf S N Fehrmann, MD, Rob S van Binnendijk, PhD, Prof Anne-Marie C Dingemans, MD, Prof Egbert F Smit, MD, T Jeroen N Hiltermann, MD, Gerco den Hartog, PhD, Mathilda Jalving, MD, Tatjana T Westphal, Arkajyoti Bhattacharya, Marieke van der Heiden, PhD, Prof Guus F Rimmelzwaan, PhD, Pia Kvistborg, PhD, Prof Christian U Blank, MD, Prof Marion P G Koopmans, PhD, Prof Anke L W Huckriede, PhD, Prof Cecile A C M van Els, PhD, Nynke Y Rots, PhD, Prof Debbie van Baarle, PhD, Prof John B A G Haanen, MD, Prof Elisabeth G E de Vries, MD

Background

Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients with solid tumours receiving systemic cancer treatment are scarce. Therefore, we aimed to assess the impact of immunotherapy, chemotherapy, and chemoimmunotherapy on the immunogenicity and safety of the mRNA-1273 (Moderna Biotech, Madrid, Spain) COVID-19 vaccine as part of the Vaccination Against COVID in Cancer (VOICE) trial.

Read more in The Lancet